Integrative Tumor Board: Esophageal Cancer
Preface Professional journals serve as critical avenues to promote communication of new research findings and syntheses of scientific information throughout the medical community. There can be a delay, however, in the application of such scientific information to actual clinical practice. In the field of integrative cancer care, this normal delay is complicated by the implementation of many techniques of alternative, complementary, and traditional medicine before scientific validation. Both of these patterns can leave the practitioner scrambling to understand new trends in the field. To begin to address the problem of advancing clinical practice and understanding in integrative cancer care, this journal will feature an article series called the Integrative Tumor Board.
The Integrative Tumor Board is a forum unique among journal-based tumor boards. It is modeled on the activities of a hospital tumor board but is based on an integrative cancer medicine perspective. In typical tumor boards, a physician will present standard clinical data on a case, and several medical specialists will then comment on the case from their own perspectives. The unique feature of the Integrative Tumor Board is that in addition to comments from medical specialists, practitioners of a variety of complementary, alternative, or integrative disciplines will provide their analyses of each case. Final comments will be made at the end of the practitioner contributions, pointing out particularly interesting features, or raising issues or concerns; comments are supervised by the journal's editor-in-chief in consultation with experts in several relevant disciplines. The Integrative Tumor Board will be presented in most or all issues of Integrative Cancer Therapies; they will be composed of recommendations of rotating panels of medical specialists and other practitioners.
It is important that the reader understand some of the basic premises of the Integrative Tumor Board.
1. Suggestions in the Integrative Tumor Board should not be construed as recommendations for medical treatment. If a patient reading this material is interested in implementing suggestions made in this feature, he or she should discuss them with a physician and other experienced health professionals familiar with his or her medical history. Appearance of various suggestions for intervention in Integrative Tumor Board articles should not be construed as endorsements of these interventions by the journal's editorial staff or members of any of its editorial boards. We do not expect readers to agree with all tumor board recommendations. Specific problem areas in tumor board suggestions will be noted in the comments, especially in areas that might pose potential risks; we will not, however, discuss every area of disagreement.
2. Recommendations in the Integrative Tumor Board are not presented as an example of how patients should be treated from an integrative medicine perspective. Actual treatment at an integrative clinic requires regular interaction and exchange between the cooperating practitioners and overall supervision by a physician who is aware of the potential contributions of the various disciplines represented in the clinic. The Integrative Tumor Board is, rather, a venue to present perspectives of a variety of disciplines important in integrative cancer care in a public forum. Its purpose is to promote knowledge and understanding of these perspectives by all health professionals working with cancer patients, since a majority of cancer patients today are taking advantage of one or more integrative therapies. We will try to encourage important areas of synergy and point out potential negative interactions (e.g., drug-herb interactions), recognizing that adequate management of both is fundamental to truly integrative care. However, this is not easily accomplished when practiced within a single facility, let alone when bringing together many modalities from several different practitioners. Still, we will attempt to address as best we can the more relevant interrelationships.
3. Not all of the suggestions made in Integrative Tumor Board articles will be solidly evidence based, particularly because some aspects of integrative care fall into a category one might call intangibles. Still, we are encouraging integrative practitioners to make an attempt to anchor suggestions in scientific evidence, or at least to submit suggestions that are not unreasonable from a scientific or psychological viewpoint, or from a traditional medicine perspective in the articles submitted by practitioners from various schools of traditional medicine.
4. We expect that the many evidence-based or scientifically reasonable suggestions in Integrative Tumor Board articles will be viewed with seriousness even by readers accustomed to working in a conventional medicine perspective. Such readers may be startled, however, by some of the less evidence based suggestions or by the spiritual counseling that will be offered by some practitioners. Conventionally oriented health professionals should realize that their cancer patients may indeed be seeing practitioners who work from less evidence-based perspectives. We strongly feel both that this is a relevant aspect of integrative care and that it is important that health professionals understand the nature of such perspectives, and some of the potentially healthful (or unhealthful) practices they prescribe. This is essential information for those electing to work constructively with patients who are using practices of alternative, complementary, and traditional medicine in coping with their illnesses. 5. As will become evident in the Case Presentation, the information given to contributing practitioners is the clinical data obtained before counseling the patient on an integrative intervention. The initial case also includes information on lifestyle and psychosocial issues of the patient taken from a comprehensive questionnaire administered at the clinic of the presenting physician. Many laboratory analyses, and all traditional medicine diagnostic techniques, are absent from the presentation. This limits the ability of practitioners to make specific recommendations for the patient, as several have noted. In response, however, most of the practitioners have made their own recommendations for laboratory analyses and other diagnostic techniques. In these recommendations, one can perceive the types of clinical analysis used in each discipline included in the Integrative Tumor Board-information that is surely as useful as specific clinical suggestions in developing understanding of integrative approaches to cancer. Many readers will find the volume of information included in the Integrative Tumor Board articles overwhelming. This reaction is, in fact, typical of those attending hospital tumor boards as well. We also feel that it is true that integrative care itself can seem overwhelming to both practitioners and patients, particularly those just beginning their encounters with the field. This is not an irrelevant issue when working with patients already facing circumstances surrounding their illness and treatments that are burdensome in and of themselves. As we have found in patient care, and as we trust will occur with those of you new to integrative cancer treatment, you will become more familiar with the various practices that will be included in the Integrative Tumor Board, and this sense of being submerged in information will diminish. We hope that the tumor board series will advance comprehension of both the conventional medical interventions and the complementary, alternative, and traditional medicine interventions on the part of health professionals and patients as this new approach to cancer care grows and develops.
Esophageal Cancer Introduction
Our patient in this issue is a classical example of one type of integrative care patient: someone who has had the definitive conventional treatment for her cancer and seeks further counseling as to what she can do next. As will be seen, she has esophageal cancer, for which only a limited number of conventional options presently exist. Thus, an integrative plan may indeed be her optimal strategy at this time. Integrative and conventional practitioners approach her with questions : What can she do to prevent a recurrence? How can she cope with the side effects of her treatment?
What can she do to find meaning in her life, which has been so altered by this unexpected and life-threatening disease?
Case Presentation
A 63-year-old woman began experiencing dysphagia especially with large mouthfuls in November 2000. The pain became progressively worse; hence, she saw her family doctor who recommended that she see a gastroenterologist. The gastrointestinal specialist arranged an esophagogastroduodenoscopy. Endoscopy pathology report of December 20, 2000, did not reveal any gross tumor or Barrett's epithelium. The distal esophageal biopsy revealed acute inflammation, and the gastric biopsy was positive for mild chronic inflammation. The pathology report of the distal esophagus was reread, which revealed hyperplastic squamous mucosa with dysplastic glandular epithelia worrisome for adenocarcinoma. The staging computed tomography of the chest/abdomen/pelvis was unremarkable.
In January 2001, the patient experienced chest pains and was admitted to the coronary care unit, where she underwent a complete cardiovasculai workup that did not reveal any evidence of coronary artery disease. The patient was sent home and started on Priloseco 40 mg/day. The patient continued to experience dysphagia, and a repeat endoscopy again revealed gastroesophageal junction inflammation.
On February 22, 2001, an esophageal ultrasound was performed that revealed a mass in the distal esophagus into the proximal stomach with transmural infiltration and regional lymphadenopathy; biopsy revealed invasive grade 2/4 adenocarcinoma of the distal esophagus. The gastric biopsy was positive for adenocarcinoma in situ.
Computed tomography of the chest showed a mass in the region of the esophagus-gastric junction consistent with the patient's known neoplasm. The mass had an irregular/lobular contour. There were prominent lymph nodes adjacent to the mass, which likely represent tumor extensions/metastases. Computed tomography of abdomen and pelvis showed no distant metastasis. Mammogram and Pap smear were within normal limits. The patient was seen by a medical oncologist who recommended concurrent chemotherapy and radiation. She was started on neoadjuvant chemotherapy continuous infusion of 5-FU and cisplatin. She received her first chemo on March 6, 2001. The patient had a J-tube placed because of persistent nausea/vomiting and dysphagia. The chemotherapy was given along with radiation, and she subsequently received 4500 cGy in 25 fractions. The patient had an extraordinarily difficult time with her treatment, with much nausea and vomiting, and ultimately a feeding tube was used. Due to significant toxicity, week 5 of the 5-FU was not administered. Patient subsequently underwent surgery on May 8, 2001. An Ivor Lewis esophagogastrectomy procedure was performed, and her postoperative convalescence proceeded along nicely without major complication or difficulty.
Final pathology revealed invasive grade 3 adenocarcinoma ; predominantly submucosal mass 3 x 2.5 x 2 cm in size. It was located at the gastroesophageal junction. The tumor infiltrated through the muscularis propria. All margins were free of tumor. Three of 5 lesser curvature lymph nodes did show evidence of metastatic disease. Abnormal laboratory results: Hemoglobin low (11), hematocrit low (33), MCV low (79.4), red blood cell dist. wid. high (16.8) , lymphocytes low (0.67), MPV low (6.8), albumin low (3.4), total white blood cell low (3300), number of CD3+ (T cells) low (810), percentage of CD4+ (T helper cells) high (41), oxidized LDL antibodies high (1006), lipid peroxides high (0.99), alpha tocopherol high (65.9), lycopene high (0.91).
Dietary history: Childhood and adult diet: American. Patient consumed a diet that was mostly chicken and fish. She rarely consumed red meat, probably once every 3 to 4 months. She had moderate amounts of refined sugar and dairy. Her average adult weight was 165 pounds prior to cancer diagnosis. Height is 5'5&dquo;. Postcancer diagnosis weight is 133 pounds. Currently eats almost all meals at home, in dining room. Uses gas for cooking. Now tries to avoid sugar and fat but will eat almost anything due to lack of appetite after surgery. Spicy flavors are favorite. Almost complete disinterest in food and diminished appetite since surgery May 2001, but forces herself to eat to maintain weight. Before surgery had lively interest in food, recipes, and cooking; probably overate.
One-day diet (before integrative nutrition intervention) : Breakfast: yogurt, banana, toast (peanut butter/ jam), orange juice. Lunch: tuna and tomato salad, crackers. Dinner: fish, potatoes, green beans. Snacks: commercial weight maintenance shake. Beverages: apple juice, water. Ninety-nine percent of meals are eaten at home, and 99% of foods are cooked. Most intense food cravings are for pasta and pizza, but patient tries to avoid processed foods; least intense cravings are for red meat.
Exercise history: Prior to cancer diagnosis, patient exercised every day, mostly walking or swimming 1 to 1.5 hours per day. She would occasionally jog or lift weights using the Nautilus machine in the local university health club in the past. Postsurgery, the frequency of exercise decreased to approximately 50%. Current exercises: swimming, walking, bicycling, gardening, breath exercise. She also did qi gong-19 postures.
Musculoskeletal issues: No problems reported with posture, gait, or coordination. Supplement history: Patient has always taken supplements. Prior to diagnosis, she took a multivitamin with kelp, and cod liver oil.
Emotional/stress factors: Patient characterizes herself as a fearful person, always worrying. She has a deep faith in God and the body's ability to heal itself. She has tried to maintain a positive attitude throughout the course of her illness.
Marital/home issues: Patient characterizes her marriage as very loving and reports that she and her husband are supportive of each other. Husband is healthy. Current symptoms/date started: Dizziness on change of position (June 2001 ) , difficulty swallowing (November 2000) , chest pain (January 2001), shortness of breath when ascending 1 flight of stairs (since surgery), belching (since surgery), getting up 3 times at night to urinate, avoiding foods (hard crusts) (since surgery), trembling in extremities (hands) (since surgery), fatigue with no obvious reason (since surgery), change in hair texture (since surgery).
Life patterns: Childhood regarded as happy; middle child. More recent concern about adult children. During working career, had stress due to expectations for job performance. Wishes to let go of anxiety, concern about adult children, keep positive attitude about cancer. Activities for relaxation: exercise, reading, needlework, and travel. Interested in good diet, exercise, and relaxation techniques. Currently uses some tapes for imaging relaxation and has made an area at home to meditate (20 minutes per day). Enjoys being outdoors, adapts well to change. 
Radiation Oncology Analysis
This presentation highlights many of the tenets of multidisciplinary approaches to cancer care that have been fostered in recent years to maximize symptom management, local control, and overall survival, especially for patients with good performance status. This woman's symptom presentation for esophageal cancer is typical: dysphagia progressing over months, yet accompanied by initial negative diagnostic evaluations. Risk factors including smoking, alcohol, and possibly reflux (Pepcid AG° use) coupled with chronic life stressors are noteworthy, and with persistence, pathology becomes evident. In the United States, esophageal cancers constitute approximately 5% of all diagnoses, usually in a 3:1 male:female ratio, with an increasing predilection for distal esophageal and gastroesophageal junction locations, felt to be related to heightened incidences of chronic reflux states and the metaplastic transition from squamous to gastric mucosal surfaces, and the development of Barrett's lining, although not confirmed in this instance. Her diagnostic evaluation, appropriately comprising esophagogastroduodenoscopy and subsequent demonstration of an adenocarcinoma on pathology review, is all too common against a backdrop of a chronic inflammatory state, sometimes found in association with chronic gastric infections such as Helicobacter Pylori although testing for this is not noted.
Once the diagnosis is established, traditional clinical staging evaluation is paramount to accurate pretreatment tumor burden assessment and, thus, both staging and sequencing of interventions. The original computed tomography chest/abdomen/pelvis being negative in December 2000, and then suggestive of anatomic irregularities reflects the likelihood that the patient's local disease volume was relatively rapidly escalating, with quicker volume-doubling times for tumor; one notes the lobulated, irregular features of the gastroesophageal junction, which can be difficult to interpret relative to adequate oral contrast distension and accurate imaging, but is consistent with locally advanced, likely transmural, disease. In distal esophageal and gastroesophageal junction tumors, regional nodes include paraesophageal, pericardial, and various regional stomach nodal sites, which are presumptively positive given their evolution over a few months and size differential. Recent advances in esophageal ultrasound have enhanced
